Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
AR-A 014418Cat. No. 3966 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea |
Biological Activity
Selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104 nM). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 μM) and over 26 other kinases. Inhibits β-amyloid-mediated neurodegeneration in hippocampal slices.Licensing Information
Sold with the permission of AstraZeneca UK Ltd.Certificate of Analysis / Safety Data Sheet
References
Bhat and Budd (2002) GSK3α signalling: casting a wide net in Alzheimer's disease. Neurosignals 11 251. PMID: 12566926.
Bhat et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J.Biol.Chem. 278 45937. PMID: 12928438.
Gould et al (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int.J.Neuropsychopharmacol. 7 387. PMID: 15315719.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: AR-A 014418, supplier, ARA014418, glycogen, synthase, kinase, 3, GSK-3, GSK3, inhibitors
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Kinases Product Listing
Highlights over 350 products for kinase research. Request a copy or view PDF today.
Kinase Inhibitor Toolbox
80 Kinase inhibitors
pre-dissolved in DMSO
Some of the most potent
kinase inhibitors all on one plate
Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
The Neurobiology of Alzheimer's Disease
Written by Alan Palmer
'The Neurobiology of Alzheimer's Disease' summarizes structural and functional changes observed in the progression of AD.
New Products in this Area
Potent MSK1 inhibitor; also inhibits other AGC group kinases
LH 846Selective casein kinase 1δ inhibitor
PPY APotent inhibitor of Abl T315l mutant and wild-type Abl kinases
Flavopiridol hydrochlorideCyclin-dependent kinase inhibitor
GSK2578215APotent, selective LRRK2 inhibitor; brain penetrant
AmlexanoxInhibitor of TBK1 and IKKε; antiallergic agent
PF 05212384Potent and selective dual PI 3-kinase/mTOR inhibitor
PF 03814735Aurora kinase A and B inhibitor
PF 04691502Dual PI 3-K/mTOR inhibitor
TNPInhibitor of IP6K; also inhibits IP3K
ACHPSelective IKKα and IKKβ inhibitor
PD 0332991 isethionatePotent, selective Cdk4/6 inhibitor; brain penetrant
CZC 24832Selective inhibitor of PI 3-Kinase γ
LY 333531 hydrochlorideProtein kinase C inhibitor; selective for β isozymes
PF 06465469Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK
10Z-HymenialdisinePan kinase inhibitor; potently inhibits MEK-1
CP 690550 citratePotent JAK inhibitor
WYE 687 dihydrochloridePotent and selective mTOR inhibitor
Tocris Events
Win a Kindle
Federation of European Biochemical Societies Congress 2013
July 6 - 11, 2013
St. Petersburg, Russia
Booth Number: 128